



GREY INNOVATION VENTURES I, LP

\$100M ESVCLP 'IMPACT' FUND

We fund the technologies to benefit
people & the planet

CONFIDENTIAL

GREY INNOVATION INVESTMENT PARTNERS PTY LTD

ACN 640 474 728

AUTHORISED REPRESENTATIVE 1283807

OF AUSTRALIAN FINANCIAL SERVICES LICENSE 334 906



Disclaimer and important information

This document is issued by Grey Innovation Investment Partners Pty Ltd ACN 640 474 728 (“Investment Partners”) on the terms and conditions set out below for the exclusive use of the persons to whom it is addressed and their advisers solely in connection with a proposed investment in the Grey Innovation Ventures Fund I (“the Fund”). It may not be used for any other purpose or by any other person. The information contained herein has been prepared to assist the recipient or their advisers in making their own evaluation of the Fund and does not purport to contain all the information that a purchaser of interests in the Fund may require. This document does not constitute an offer or invitation for the sale, purchase, exchange or transfer of any interests in the Fund or any recommendation to enter into a transaction and is not intended to form the basis of any contract or investment decision. This document is only being sent to persons reasonably believed by Investment Partners to be investment professionals or to persons to whom it may otherwise be lawful to distribute it pursuant to s708 of the Corporations Act. If you are not such a person, please return this document to Investment Partner’s registered office as soon as possible and take no other action.

To the extent permitted by law, none of Investment Partners nor its affiliates, nor their respective directors, employees, agents or advisers, make any representation or warranty (express or implied) as to the accuracy or completeness of this document or any other written or oral communication transmitted to prospective purchasers in the course of their evaluation of Investment Partners. Investment Partners does not undertake any obligation to provide any additional information or to update this document or to correct any inaccuracies which may become apparent. This document includes certain statements with respect to the anticipated future performance of the company and as to the markets for its services. Such statements reflect various assumptions that may or may not prove to be correct. To the extent permitted by law, no representation or warranty (express or implied) is made by Investment Partners or its respective directors, employees, agents or advisers as to the reasonableness of such statements.

The information contained in this document and any further information relating to Investment Partners supplied by Investment Partners or its respective directors, employees, agents or advisers is and will be supplied on the basis that, to the extent permitted by law, neither Investment Partners nor its directors, employees, agents or advisers shall be liable (except in the case of fraud) for any errors or omissions or any direct, indirect or consequential loss or damage howsoever arising sustained by any person relying on such information and any such liability is expressly disclaimed. This document is provided on the express understanding that the information contained herein will be regarded and treated as strictly confidential and in accordance with the terms of a confidentiality agreement in force between Investment Partners and the recipient. Recipients not wishing to pursue the transaction must return this document to Investment Partners immediately.

The distribution of this document in certain jurisdictions may be restricted by law and such distribution could result in violation of the laws of such jurisdictions. Persons into whose possession this document comes should inform themselves about and observe any restrictions and legal requirements in relation to the distribution of this document and the participation in any proposals as set out in this document. Any failure to comply with these requirements may constitute a violation of the laws of the relevant jurisdiction. This document does not constitute an offer of, or the solicitation of an offer to subscribe for or buy, any securities to any person in any jurisdiction to whom it is unlawful to make such offer or solicitation in such jurisdiction. By accepting this document you agree to be bound by the foregoing limitations.

With a \$100M Early Stage Venture Capital Limited Partnership (ESVCLP), Grey Innovation Investment Partners (the Manager) is decreasing the traditional risk of the ESVCLP model by investing in sophisticated start-up companies. With first market access to Grey Innovation Group's suite of companies in, or approaching early revenue stage, the risk is significantly reduced.

As an **ESVCLP fund with a strong ESG focus**, 0% Capital Gains Tax and a significant tax credit. Unprecedented government funding of over \$23B is available for the sectors aligning with our portfolio and mandate.

**Now is our time to
make an impact.**

Grey Innovation Group is recognised internationally for operating a scalable platform to unlock the best IP and fast-tracking it to commercial success. Its model of repeating the startup process across multiple sectors allows for a unique and successful skill set.

Its proven track record and relationships with institutions, industry and governments puts Grey Innovation Group at the forefront of unrealised IP opportunities.




History

Since
1998

Established 1998, Grey has a history of solving complex problems for leading companies whose **combined market caps are now \$2B+**


Global presence



Headquarters in Melbourne with operations in New Zealand, Singapore, Germany and the US

 **35+**

35+ direct staff
100 staff across portfolio companies with deep commercial and technical skills



Operates a **scalable platform** for identifying, licensing, developing and commercialising IP to create substantial new companies

Our sectors



Active in **Medtech, Cleantech and Homeland Security** sectors, solving hard and significant problems leveraging hardware and software




Strong relationships with over 30 universities, research institutions, Government and leading industry technology players

The Australian government R&D Tax Incentive provides a benefit through a refundable tax offset of **43.5%**



\$50M+

Accessed non-dilutive funding from domestic and international government agencies



Built the Grey Innovation Group portfolio, of **7 diversified assets**, over 5 years to **\$177M+ value**

Grey Innovation Group initial investment portfolio

Investors gross IRR is
currently >30% pa

COMPANY	STAGE	GREY OWNERSHIP	COMPANY VALUATION A\$M	PORTFOLIO VALUATION A\$M	VALUATION METHODOLOGY*	TOTAL RAISED A\$M
Eco Detection Pty Ltd	Commercialisation	40.19%	42.11	16.92	Raise in progress ¹	15.06
Firefly Health Pty Ltd ⁶	Development	31.00%	13.61	4.22	Valuer ²	4.94
GreyScan Pty Ltd	Revenue generating	24.75%	77.25	19.12	Last raise ³	28.54*
TALi Digital Pty Ltd	Listed ASX:TD1	4.70%	34.01	1.60	Public market ⁴	18.2
Cardia Pte Ltd ⁶	Development	44.25%	9.52	4.21	Raise in progress ¹	1.55
Track Alert System Holdings Pty Ltd	Development	68.0%	.83	.56	Valuer ²	- **
TOTAL			177.33	46.64		*7.69 under con note **no capital raised

Notes:

1. Raise in progress is valued based on the current priced round that is yet to close
2. Value is based on a third-party company valuation commissioned by Grey Innovation Pty Ltd
3. Last raise is the last post-money valuation at a capital raising event
4. 30 Day VWAP
5. Cardia Pte Ltd is commercialising Safehouse Innovation Limited IP
6. Grey Innovation owns Convertible Notes in Firefly Health Pty Ltd and Cardia Pte Ltd which are not accounted for in this Asset Valuation (SGD1 = AUD1)


*Governments have announced severe measure to counter the impact of COVID-19. The impact of these measures is uncertain on supply and demand drivers of valuations. Whilst we have sought to consider these impacts on our valuations, based on the dynamic and evolving information available, there is uncertainty as to the extent and duration of these impacts. The factors driving these conditions can change over short periods of time and their impacts on valuations may need to be reassessed periodically.

The Relationship

Grey Innovation Group (GIG)
&
Grey Innovation Investment Partners (GIIP)

- GIIP has an Independent Investment Committee including valuation determination (external as required)
- GIG provides discounted (25%) services to their startup companies and GIIP portfolio companies
- GIG grants first right of refusal to GIV Fund
- GIG investing \$2.5M into GIV Fund
- GIG earns 20% of Fund Carry. GIIP executives/team earns 80% of Fund Carry

Organisational Chart




Deal flow structure

**GREY INNOVATION GROUP
PORTFOLIO COMPANIES**




FUTURE COMPANIES

First market access to
Grey Innovation Group's
reduce risk portfolio



The structure



Impact investing

We strive for a positive ESG impact alongside strong financial returns.

The future of Environmental, Social and Governance (ESG) lies in the commercialisation of technology that focuses on responsible and sustainable operations and outputs. GIIP seeks to invest in early-stage technology that improves lives and benefits the planet.

Strict ESG mandates and policies underlining the Fund are critical for thorough risk analysis and decreasing overall portfolio risk.

We consider ESG risks and opportunities throughout every step of the investment process and apply our strict responsible investing principles to all investments within the Fund.



From inception, Grey Innovation Group (GIG) portfolio companies have a strong ESG focus. Future planning leads to decreased risk.

Impact investing

The key to a sustainable future is the commercialisation of technology that focuses on responsible and sustainable operations and outputs without causing harm or depleting natural resources.

As a signatory of the UN Principles of Responsible Investment (PRI), Grey Innovation Investment Partners (GIIP) commits to ESG transparency and accountability. The PRI is a set of six voluntary and aspirational principles for incorporating and reporting on ESG throughout the investment process. GIIP has committed to abide by and report on the PRI. GIIP will also focus on UN Sustainable Development Goals, where the most significant impact can be achieved.

EXCLUSIONS COMMITMENT

No direct investment in companies that derive revenue from;

- controversial weapons
- tobacco

No investment in companies that partake in;

- high levels of pollution/waste generation
- higher than medicinal levels of nuclear waste generation
- animal testing where a viable alternative is available



Signatory of:




**Billions of dollars are
spent on research that
never makes it to market.
This is our hunting
ground.**

Deal flow

Grey Innovation Group operates a scalable platform to fast track the commercial success of start-ups.

The Fund has first market access to Grey Innovation Group's pipeline of sophisticated start-ups with skilled teams, initial customers and ready for scaling. Established partner relationships with leading global universities, research institutes and government, as well as expert manufacturing and distribution partners, all lead to significantly reduced risk.

REPEATABLE PROCESS - REDUCING THE RISK



20+ years of refining the commercialisation process of start-ups

Trace detection technology

Grey Innovation Group used its unique skillset & scalable platform to take the initial GreyScan technology & adapt it for further commercial opportunities.

This breakthrough technology has been adapted into the pharmaceutical industry, with immediate demand.



Trace detection analyses non-visible 'trace' amounts of particles on a surface or in the air. GreyScan's technology is fast, accurate, portable and cost-effective, making it vastly superior to the incumbent technology.

EXPLOSIVE TRACE DETECTION (ETD)

GreyScan has developed the world's first automated inorganic trace detection device. portable, accurate and easy to use. **Current ETD market value US\$1.6B.**

PHARMACEUTICAL TRACE DETECTION (PTD)

Quality management, inline cleanliness checks between batches of drug production. The current shutdown between batches is up to 5 days, GreyScan's technology is <1 day. The **PTD expected market value >US\$4.26B by 2026**

TRACE VIRUS DETECTION (TVD) ENVIRONMENT & BREATH TEST

Confirmation of the presence or absence of a virus on a surface or airborne. Non-invasive accurate testing of COVID-19 and future viruses in <3mins. Global point of care diagnosis **expected market value US\$50.6B by 2026.**

CURRENT CUSTOMERS & COLLABORATORS





Revolutionary water quality monitoring

Grey Innovation Group's portfolio company, Eco Detection, puts the laboratory in the field. The remote water quality monitoring system uses advanced sensors to provide real-time data via a fully managed platform. The platform is a managed service, creating continued after-sales revenue. The real-time approach empowers industry, government, and organisations to preserve and improve water quality and meet compliance obligations.

Real-time monitoring, as delivered by Eco Detection, is a key reform announced in the New Zealand Government's National Policy Statement on Freshwater Management 2020 and the company is working with both the Ministry for Environment and Ministry for Primary Industries to develop nationwide multi-year catchment monitoring programs for rollout in 2022.

In Australia, a 3-year project funded by The Ian Potter Foundation and supported by the government, EPA and industry will commence in the River Derwent catchment in early 2022.

Product rendering of commercial nitrite/nitrate sensor



The logo for 'canopy blue' features a stylized tree silhouette composed of white binary code (0s and 1s) on the left, and the words 'canopy blue' in a white, lowercase, sans-serif font on the right. The background is a deep blue gradient with an underwater scene of green seaweed.

Global seaweeds market will be

US\$28.9B¹

by 2027 expanding at CAGR of 9.2%

Asia Pacific is currently the largest market today accounting for 75% of global revenue in 2019. Seaweed industry in Asia is typified by small scale, rope grown, labour intensive farms.

The Australian market is burgeoning and ripe for expansion. Government policy is driving innovation.

1. Commercial Seaweed Market Analysis 2020, Grand View Research

2. <https://sitn.hms.harvard.edu/flash/2019how-kelp-naturally-combats-global-climate-change/>



Grey Innovation Group is building the infrastructure to commercially cultivate seaweed, in the ocean, on a large scale. Seed funding is being raised and conversations and negotiations with prospective customers and partners are taking place.

Emerging blue carbon credits

Seaweed can sequester up to 20 times² more carbon per acre than land forests with some species growing up to 65 metres in height.

The seaweed market has the potential to achieve significant financial returns for investors while helping to drive industry growth with positive environmental and social impact.

Now is our time.

Unprecedented funding aligns with our portfolio and mandate.

\$1.9 billion

Australian Renewable Energy Agency (ARENA) and Clean Energy Finance Corporation (CEFC) to fund low emission technologies.

\$300 million

Advancing Hydrogen Fund (Federal Government) (run by the CEFC)

\$1.3 billion

The Manufacturing Translation and Integration Streams aims to help manufacturers translate good ideas into commercial outcomes. This forms part of the Modern Manufacturing Initiative (MMI).

\$20 billion

Medical Research Future Fund (Federal Government)

Plus many more millions in ongoing grants for Cleantech and Medtech

R&D Tax Incentive - 43.5% credits on research and development

People



MATT MCNAMARA
MANAGING DIRECTOR



ELIZABETH COURT
NON-EXECUTIVE
DIRECTOR



SUSAN OLIVER AM
NON-EXECUTIVE
DIRECTOR



JEFFERSON HARCOURT
EXECUTIVE DIRECTOR



ADRIAN CRITCHLOW
CHIEF INVESTMENT OFFICER



BEN KILMARTIN
INVESTMENT COMMITTEE



MANDIE LAMMENS
GREY INNOVATION GROUP
COMPANY SECRETARY
INVESTOR RELATIONS
OFFICER



EMILY RYAN
ESG OFFICER



WANI WALL
GREY INNOVATION GROUP
BRAND & COMMUNICATIONS
EXECUTIVE

The Manager's track record

MATT MCNAMARA, MANAGING DIRECTOR

IB Australian BioScience Fund I

Principal involved: Matt McNamara (CIO)

- 2008 - 2014
 - IRR = 22.5% net of fees to investors
 - A\$41.8M Funds Under Management (**FUM**), A\$35M Called, \$60M returned to investors
 - (Capital Return/Distributions by 31 March 2014)
 - 12 investments, 12 exits
 - Top quartile Ex US PE/VC Fund
- (Source: Cambridge Associates PE & VC Benchmarks Q1 2014)

Asia Pacific Healthcare Fund II

Principal involved: Matt McNamara (CIO)

- September 2012 – Dec 2019
- A\$55,775,000 **FUM** committed
- \$53,790,573 Called (Dec 19)
- PE style 5 + 5-year fund
- 7 investments private and public
- IRR = 24% (Nov 2019) (Unrealised)

BioScience Managers Translation Fund I

Principals involved: Matt McNamara (CIO)

- Dec 2016 – Dec 2019
- A\$100,000,000 **FUM** committed
- \$49,550,000 Called (Dec 19)
- PE style 5 + 5-year fund
- 6 investments private and public
- IRR = 44% (Nov 2019) (Unrealised)

Booking.com



ADRIAN CRITCHLOW, CHIEF INVESTMENT OFFICER

ActiveHotels.com - Booking.com

Principal involved: Adrian Critchlow

- 2000 - 2004
- Raised \$720K (GBP 400K)
- Series A & B \$5.4M (GBP 3M)
- Won Deloitte Fast 50
- Sold to Priceline for \$230M (USD 160M)
- Seed investors received 16x return in 4 years
- Priceline market cap of USD 1B in 2004; renamed Booking Holdings with current market cap of USD 68B

Active Investment Fund

Principal involved: Adrian Critchlow

- 2005 - 2007
- Invested in 9 startups
- Alertme.com sold to British Gas for \$117M (GBP 65M)
- Varden - recently A-round funded by Horizon Ventures
- Ionscope - sold to Cronin Group PLC
- Revoo.com - running and profitable
- Texperts - sold to KGB operator of 118118 service
- I20 Water - sold to Ombu Group with 10x ROI
- WAYN - closed
- Reciva.com (sold)

SUSAN OLIVER AM, DIRECTOR

Independent member of the Investment Committee for IFM Investors Chair of Investment Committee for Victorian Government's Alice Anderson Fund

- Angel investor in 18 start-ups since 2013 of which three successful exits at 1.4 times, 4 times and more than 30 times initial capital invested, (awarded exit of the year in 2018 in Techboard's annual awards) solid and performing angel investment portfolio currently of 14 growing businesses
- Awarded Angel of the Year in 2021 in Techboard's annual Australian Angel Awards
- Judge in 'Finnies' awards 2020 and 2021

Proven track record



THE NEED

In 2020, COVID-19 forced government demand for lifesaving ventilators. Grey Innovation Group (GIG) identified the need and, without solicitation, offered the Australian Government their skills.

COMMERCIALISING THE SOLUTION

GIG assembled a local consortium of thirty local manufacturers to build the ventilators. With \$500K from the Victorian Government and \$39M from the Federal Government, GIG manufactured ~2,000 ventilators in under six months.

GIG directly contributed to strengthening investment in local technology and manufacturing, known as the "Make Australia make again" campaign. Export opportunities for the NOTUS ventilator are in discussion.



THE NEED

Over 85% of global terror incidents involve inorganic compounds, yet the 150,000+ ETDs deployed at any one time globally cannot detect them, exposing a critical weakness in the global trace detection system.

THE SOLUTION

Together with the University of Tasmania, GreyScan's developed the ETD-100, the only product in its class in the world for trace detection of inorganic compounds.

COMMERCIALISATION

GreyScan's internationally renowned reputation and trusted relationships with government and key stakeholders, has facilitated the deployment of the ETD-100. GreyScan EDT-100 customers include defence, law enforcement, first responders, and security operators responsible for public facilities and events protection (sporting arenas and concert venues).

Media

LEADERSHIP | INNOVATION | SUCCESS | COLLABORATION | BEST IN CLASS | FINANCE | LIFESTYLE

VENTURE MAGAZINE

the **DISRUPTION** issue

BAT BOOTHS
KEEPING MINERS SAFE ON SITE

POWER STRUGGLE
FOSSIL FUELS VS RENEWABLES IN THE POST-VIRUS GRID

IT'S A VIRTUAL REALITY
THE RISE OF VIDEOCONFERENCING

“I think the key is Australia needs to start investing,”
- Grey Innovation executive chair
Jefferson Harcourt

HOW CONSTRUCTION KEPT GOING AND WHY

MAKE AUSTRALIA MAKE AGAIN

GREY INNOVATION'S VISION FOR BRINGING MANUFACTURING BACK TO AUSTRALIA

'Control your own destiny': Ventilator project highlights importance of local manufacturing



HOW VENTILATORS WORK

1. Breaths enter or leave the patient through a mask or tube.
2. Oxygen enters the lungs and carbon dioxide leaves.
3. The ventilator controls the flow of air into and out of the lungs.
4. The ventilator also controls the pressure of the air.
5. The ventilator also controls the volume of the air.
6. The ventilator also controls the rate of the breaths.

Breathing a sigh of relief

\$31 MILLION DEAL TO PRODUCE 2000 LIFE-SAVING MACHINES

A \$31-million deal to produce 2000 ventilators for Australia's hospitals has been struck by ResMed, a US medical device company, and the federal government.

How ResMed beat the pack to bring ventilators into Australia

THE PLAYERS

 Mick Farrell, CEO of ResMed - the company produced 5,500 ventilators for national stockpile.	 Catherine Delamare, general manager, ANZ, ResMed - took control of local talks with the government.	 Glenn Beauchamp - chair's Health Industry Coordination Group to oversee various PPE taskforce groups.
 Greg Hunt, Health Minister - overseeing Australia's response to COVID-19.	 Karen Andrews, Minister of Industry - pushed for more local manufacturing of ventilator parts.	 Jefferson Harcourt, Grey Innovation chairman - leading an industry consortium to produce ventilators in Victoria.

TIMELINE OF KEY EVENTS

- Early Jan 2020 ResMed boss Mick Farrell gets news that Wuhan hospital customers are supplying orders of ventilators.
- Jan 30 WHO calls COVID-19 a global health emergency.
- Mid-Feb Australian government begins talks with ResMed about ventilator needs.
- Mar 21 Glenn Beauchamp returns from retirement to help coordinate COVID-19 PPE response.
- Mar 31 ResMed triples ventilator production to 52,000 units in three months.
- Apr 2 White House enacts Defense Production Act to help ventilator producers.
- Apr 30 ResMed delivers 5500 ventilators to national stockpile.

Coronavirus shortages prompt Australia to bring manufacturing home

Critics say the country's economy is vulnerable because of its reliance on China

1.5MH 03/05/2020 2. Herald Sun 10.04.2020 3. The Australian 21.04.2020 4. Australian Financial Review 23.05.2020 5. Financial Times 15.04.2020 6. Manufacturers' Monthly April 7. Financial Times 15.04.2020

Ventilator stockpile up by 3000

HOSPITALS

NATASHA ROBINSON
SARAH EBBS

The number of intensive care ventilators in Australia has surged, with thousands of the machines being manufactured and delivered to the federal government.

Staff at medical device company ResMed have worked overtime during the past month to provide more than 3000 ventilators, which keep patients alive when they can no longer breathe on their own.

There were an estimated 2023 intensive care beds in hospitals across the country that were fitted with ventilation when the crisis began. The federal government has set a target of having 7000 ventilators available for use.

ResMed has been contracted to supply 2000.

The extra 300 ventilators that were not included in the contract will be held by the federal government in the COVID-19 national stockpile to be distributed when hospitals require them.

Industry Science and Technology Minister Karen Andrews said the delivery from ResMed followed extensive work to secure overseas production.

"The government has been working hard to secure supply and increase the domestic manufacturing of ventilators," Mr Andrews said. "ResMed is a wonderful Aussie manufacturer that has stepped up in these unprecedented times to ramp up its production."

"ResMed is a terrific example of the incredible manufacturing capacity that Australia has right here at home and shows how Aussie ingenuity can save lives."

Ventilators help a patient breathe by assisting the lungs to inhale and exhale air. A light attached to the ventilator is inserted into a patient's mouth or nose and fed down the windpipe, or alternatively inserted through a respiratory tube into the work.

Oxygen-rich air is fed into the lungs and carbon dioxide is removed.

There are currently 120 patients being treated for COVID-19 in Australian hospitals.

Forty-nine are in intensive care, with 22 requiring ventilators.

Health Minister Greg Hunt said as well as an additional 2000 ventilators to be supplied by ResMed in coming weeks, there were a further 2000 being made by another Australian company, Grey Innovation, together with a consortium of local manufacturers and engineering firms.

"These additional ventilators will help to ensure we have sufficient supplies to meet the increased demand we expect in coming months," Mr Hunt said.

"Our national aim over the next few months is simple — suppress the virus, increase our testing and tracing, and slowly ease the restrictions."

Hospitals have already boosted their number of intensive care beds with ventilators attached by repositioning anaesthetic and intensive care beds.

NSW Health said it had dis-

“Everyone assumes we can just buy stuff from China but that just isn't the case. Everything is finite”

Jefferson Harcourt, Grey Innovation

Commonwealth joins Vic gov in funding for ventilator manufacturing

The federal government has joined the Victorian government in supporting the manufacture of ventilators in Australia, and will fund the production of 2000 machines.

The federal government has joined the Victorian government in supporting the manufacture of ventilators in Australia, and will fund the production of 2000 machines.

The federal government has joined the Victorian government in supporting the manufacture of ventilators in Australia, and will fund the production of 2000 machines.

Aussie breath test answers infection question in just three minutes

ANTHONY DENKHAM

Chief executive Sam Ollerton said the breath test, which answers the question of whether someone has COVID-19, was not yet to be submitted to health regulators for approval.

The breath test works in under three minutes, Mr Ollerton said. "But we haven't gone to the Therapeutic Goods Administration yet. This will all be done in the next few weeks."

Mr Ollerton said the breath test would also be used to identify COVID-19 cases in schools and other public places.

There are currently 120 patients being treated for COVID-19 in Australian hospitals.

Forty-nine are in intensive care, with 22 requiring ventilators.

Health Minister Greg Hunt said as well as an additional 2000 ventilators to be supplied by ResMed in coming weeks, there were a further 2000 being made by another Australian company, Grey Innovation, together with a consortium of local manufacturers and engineering firms.

"These additional ventilators will help to ensure we have sufficient supplies to meet the increased demand we expect in coming months," Mr Hunt said.

"Our national aim over the next few months is simple — suppress the virus, increase our testing and tracing, and slowly ease the restrictions."

Hospitals have already boosted their number of intensive care beds with ventilators attached by repositioning anaesthetic and intensive care beds.

NSW Health said it had dis-

Test del respiro per capire chi ha contratto il Covid e quanto è contagioso: dura 3 minuti

Groundbreaking coronavirus BREATH test that could see international borders reopen

Coronavirus, nuovo test in Australia: in 3 minuti rivela anche quanto è contagiosa una persona

Si prevede possa essere modificato per individuare anche le varianti emergenti. Approvato nel Paese il vaccino AstraZeneca

COVID breath test from Aussie company GreyScan could open our borders

Coronavirus, nuovo test in Australia: in 3 minuti rivela anche quanto è contagiosa una persona

Si prevede possa essere modificato per individuare anche le varianti emergenti. Approvato nel Paese il vaccino AstraZeneca

Daily Mail News

Australian company develops test that will tell you if you have coronavirus in just THREE MINUTES - and all you have to do is breathe into the device

Melbourne based company GreyScan is developing the three minute breath test. They plan to roll out the breath test by the end of the year after it's approved. The test could be used in heavily populated spaces like airports and sport events. The breath test can identify how infectious a person is and is non-invasive.

Now streaming the world's best

Company entwickelt einen Test, der zeigt, ob Sie Covid-19 in drei Minuten haben.

Bereitgestellt von Daily Mail MailOnline-Logo

Ein australisches Unternehmen entwickelt einen Covid-19-Atemtest, der Ergebnisse in nur ... und bei Großveranstaltungen wie Sportwettkämpfen verarbeitet werden kann.

Samantha Ollerton, Geschäftsführerin von GreyScan, sagte, einer

Il test del respiro per capire chi ha contratto il Covid e quanto è contagioso: dura 3 minuti

Groundbreaking coronavirus BREATH test that could see international borders reopen

Coronavirus, nuovo test in Australia: in 3 minuti rivela anche quanto è contagiosa una persona

Si prevede possa essere modificato per individuare anche le varianti emergenti. Approvato nel Paese il vaccino AstraZeneca

Three breath tests in just under three minutes. This is still all laboratory testing, but the results are extremely promising. The next phase for us is commercialisation and mass manufacture. We are doing the rounds, seeking government funding to help expedite the mass manufacture

Samantha Ollerton, CEO of GreyScan

Melbourne company develops COVID-19 breath test

SUNRISE MELBOURNE

DEVELOPING STORY COVID-19 BREATH TEST

World first device could help reopen our borders sooner

SUNRISE PERTH NEWS LIVE AND LOCAL EVERY 30 MINUTES PER 27 7.37

**Now is our time to
make an impact.**

Frequently asked questions

Q.

Given the close relationship between Grey Innovation Group (GIG) and Grey Innovation Investment Partners (GIIP)/ Grey Innovation Ventures funds (GIV), how can we be satisfied the perceived conflict of interest is handled?

A.

Upon application for our ESVCLP license, DISER, the ATO and Gilbert and Tobin ensured there was not an Affiliates situation with respect to GIG and GIV shareholders. In addition, the Boards of GIG and GIIP constitute different personnel, except for Jefferson Harcourt.

Whilst GIG has afforded GIIP and GIV funds first right of refusal to all capital raisings of GIG startup companies, (after any pre-emptive rights of 'current' shareholders), GIG has no say in the investment decision. The GIIP Managing Director (Matt McNamara) & CIO (Adrian Critchlow) constitute the Investment Committee and will independently make all investment decisions.

Q.

Given GIG owns 100% of GIIP, what is the economic benefit to GIG?

A.

The General Partner, GIIP, draws modest management fees of 1.5% p.a. for the investment period and reduced to 1% for the management and divestment period. It is not anticipated the GP will make a meaningful profit from Management Fees. The economic benefit GIG and GIIP Executive team aim to make will be via outperformance of the funds. After the Limited Partners (LPs) are returned their committed capital plus a Preferred Return of 8% IRR, the over performance "Carry" will be distributed 80% to LPs and 20% to GIIP. GIIP has in turn resolved to distribute any Carry, 80% to Executives and Non Executives for their respective contribution over the life of each fund, and the remaining 20% to GIIP.

NB: GIG will also be a LP of \$1M in GIV1.

Frequently asked questions

Q.

What is the relationship/arrangement with respect to GIG startup companies and them being deal flow for GIV funds?

A.

GIG has afforded GIIP and GIV funds first right of refusal to all capital raisings of GIG startup companies (after any pre-emptive rights of 'current' shareholders).

GIV will also source deal flow, predominantly Australian, from other early stage cleantech and medtech companies from Australia and overseas.

Q.

How do GIV portfolio companies benefit from the GIG team and services?

A.

All GIV portfolio companies, not just those sourced from the GIG stable, will be able to avail themselves of GIG staff via reduced rates (25% DISCOUNT TO MARKET RATES) shared services agreements and licenses to GIG proprietary IP and software.



INVESTMENT PARTNERS

GREY INNOVATION
INVESTMENT PARTNERS PTY LTD
ACN 640 474 728

Matt McNamara

M 0438 628 862

E mattm@greyinnovationventures.com

Adrian Critchlow

M 0401 222 300

E adrianc@greyinnovationventures.com

Jefferson Harcourt

M 0401 289 292

E jefferson.harcourt@greyinnovation.com